News
Despite AMD’s overall optimism, investors were in an unforgiving mood, and earnings miss appeared to weigh heavily on its stock, which was down more than 5% in late trading. But overall, AMD’s stock ...
Now, it’s worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...
All told, the S&P 500 rose 91.93 points to 6,329.94. The Dow Jones Industrial Average climbed 585.06 to 44,173.64, and the ...
StockStory.org on MSN2h
Matthews (NASDAQ:MATW) Delivers Impressive Q2
Diversified solutions provider Matthews International (NASDAQ:MATW) reported in Q2 CY2025, but sales fell by 18.3% year on ...
StockStory.org on MSN2h
QuidelOrtho’s (NASDAQ:QDEL) Q2 Earnings Results: Revenue In Line With Expectations, Stock Soars
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) in Q2 CY2025, but sales fell by 3.6% year on year to $613.9 million.
StockStory.org on MSN2h
Toast’s (NYSE:TOST) Q2: Beats On Revenue
Restaurant software platform Toast (NYSE:TOST) announced in Q2 CY2025, with sales up 24.8% year on year to $1.55 billion. Its ...
StockStory.org on MSN3h
AMD (NASDAQ:AMD) Posts Better-Than-Expected Sales In Q2, Guides for Strong Sales Next Quarter
Computer processor maker AMD (NASDAQ:AMD) reported Q2 CY2025 results , with sales up 31.7% year on year to $7.69 billion. On ...
The ISM report showed service sector activity in June flatlined while the prices paid index rose to its highest in nearly ...
StockStory.org on MSN3h
Jackson Financial (NYSE:JXN) Misses Q2 Revenue Estimates
Retirement solutions provider Jackson Financial (NYSE:JXN) in Q2 CY2025, with sales falling 127% year on year to -$471 ...
StockStory.org on MSN3h
Vestis (NYSE:VSTS) Posts Q2 Sales In Line With Estimates
Uniform rental provider Vestis Corporation (NYSE:VSTS) in Q2 CY2025, but sales fell by 3.5% year on year to $673.8 million.
StockStory.org on MSN4h
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q2 CY2025, but sales were flat year on year at $213.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results